News and Reports
-
IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed
11 August 2025Download -
Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome’s Blood-Based Screening Test for Colorectal Cancer
6 August 2025Download -
SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics
5 August 2025Download -
Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
22 July 2025Download -
Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management
18 July 2025Download -
Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease
25 June 2025Download -
Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
22 May 2025Download -
AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas
14 May 2025Download -
Swixx and Biopas Expand Portfolio in Latin America, Securing 9 New Partnership Contracts in One Year
28 April 2025Download -
Aculys Pharma Signs 4.4 Billion Yen Series C Funding Round Agreement
24 March 2025Download -
VISEN Pharmaceuticals Announces the Offer Price and Allotment Results of the Global Offering
21 March 2025Download -
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
20 March 2025Download -
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine
17 March 2025Download -
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
10 March 2025Download -
NiKang Therapeutics® Announces First Patient Dosed in a Phase 1b/2 Study of NKT2152 in Combination with Standard-of-Care in First-Line Regimen for Hepatocellular Carcinoma
21 January 2025Download -
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta
21 January 2025Download -
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
9 January 2025Download -
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
8 January 2025Download -
Sai Life Sciences now listed on Indian Stock Exchanges
18 December 2024Download -
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
18 December 2024Download -
C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital
16 November 2024Download -
Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties
14 November 2024Download -
Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32 Program in Patients with Solid Tumors
30 October 2024Download -
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
25 October 2024Download -
OneSource, the Group’s Spec Pharm CDMO, receives equity commitments of INR 8,010 mn (USD 95 mn) from marquee investors at a pre-money equity valuation of USD 1.65 bn
16 October 2024Download